Serum levels of apoptosis inhibitor of macrophage are associated with hepatic fibrosis in patients with chronic hepatitis C

BMC Gastroenterology

Research Article

Hirohito Tsubouchi¹  Masaaki Hidaka²  Susumu Eguchi²  Kumiko Mera³  Kotaro Kumagai³  Makoto Oketani³  Akihiro Moriuchi³  Tsuyoshi Nosaki³  Tsutomu Tamai³  Seiichi Mawatari³  Hirofumi Uto³  Kohei Oda³  Yozo Yoshimine³  Akio Ido³  Kazuaki Tabu³  Yuko Shimada⁴ 

[1] Department of HGF Tissue Repair and Regenerative Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, 890-8544, Kagoshima, Japan;Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, 852–8501, Nagasaki, Japan;Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, 890-8544, Kagoshima, Japan;Miyazaki Prefectural Industrial Support Foundation, 16500-2 Higashikaminaka, 880-0303, Sadowara-cho, Miyazaki, Japan;

关键词: Apoptosis inhibitor of macrophage;    Adipocytokine;    Hepatic fibrosis;    Hepatitis C virus;    Chronic hepatitis;    Insulin resistance;   

DOI  :  10.1186/1471-230X-14-27

 received in 2013-10-16, accepted in 2014-02-05,  发布年份 2014

来源: Springer

【 摘 要 】

BackgroundApoptosis inhibitor of macrophage (AIM) and adipocytokines are involved in the metabolic syndrome, which has been putatively associated with the progression of chronic hepatitis C (CHC). However, the association between these cytokines and CHC is not fully elucidated. The aim of this study is to test whether serum levels of AIM and adipocytokines are associated with histological features, homeostasis model assessment-insulin resistance index (HOMA-IR), or whole body insulin sensitivity index (WBISI) in CHC patients.MethodsSerum samples were obtained from 77 patients with biopsy-proven CHC. In 39 patients without overt diabetes mellitus, a 75 g oral glucose tolerance test (OGTT) was performed and HOMA-IR and WBISI were calculated.ResultsA serum AIM level of ≥1.2 μg/ml was independently associated with advanced hepatic fibrosis (F2 or F3) (odds ratio [OR], 5.612; 95% confidence interval [CI], 1.103–28.563; P = 0.038) based on a multivariate analysis, but there was no significant association between AIM and hepatic steatosis or inflammation. Furthermore, a serum leptin level of ≥8.6 ng/ml was independently associated with the presence of hepatic steatosis (≥5%) (OR, 6.195; 95% CI, 1.409–27.240; P = 0.016), but not hepatic fibrosis or inflammation. No relationship was observed between levels of adiponectin or resistin and hepatic histological parameters based on a multivariate analysis. Although serum levels of leptin, resistin, and adiponectin were significantly correlated with HOMA-IR and WBISI, there was no significant relationship between serum AIM levels and HOMA-IR or WBISI, respectively.ConclusionHigh serum levels of AIM in CHC patients are potentially related to advanced hepatic fibrosis. AIM and adipocytokines are possibly associated with pathological changes via a different mechanism.

【 授权许可】

Unknown   
© Mera et al.; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.